Switch theme
Sign up to access all valuation multiples
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
NanoRepro has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, NanoRepro achieved revenue of $3.5M and an EBITDA of -$5.0M.
NanoRepro expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NanoRepro valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $41.9M | $3.5M | XXX | XXX | XXX |
| Gross Profit | $60.8M | $13.2M | XXX | XXX | XXX |
| Gross Margin | 145% | 378% | XXX | XXX | XXX |
| EBITDA | -$4.7M | -$5.0M | XXX | XXX | XXX |
| EBITDA Margin | -11% | -144% | XXX | XXX | XXX |
| Net Profit | $31.9M | -$4.0M | XXX | XXX | XXX |
| Net Margin | 76% | -115% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, NanoRepro's stock price is EUR 1 (or $2).
NanoRepro has current market cap of EUR 17.7M (or $19.0M), and EV of -EUR 13.5M (or -$14.5M).
See NanoRepro trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$14.5M | $19.0M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, NanoRepro has market cap of $19.0M and EV of -$14.5M.
NanoRepro's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate NanoRepro's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for NanoRepro and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$14.5M | XXX | XXX | XXX |
| EV/Revenue | -4.2x | XXX | XXX | XXX |
| EV/EBITDA | 2.9x | XXX | XXX | XXX |
| P/E | -3.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNanoRepro's NTM/LTM revenue growth is n/a
NanoRepro's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, NanoRepro's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate NanoRepro's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for NanoRepro and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -92% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -144% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 195% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NanoRepro acquired XXX companies to date.
Last acquisition by NanoRepro was XXXXXXXX, XXXXX XXXXX XXXXXX . NanoRepro acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| Where is NanoRepro headquartered? | NanoRepro is headquartered in Germany. |
| How many employees does NanoRepro have? | As of today, NanoRepro has 16 employees. |
| Is NanoRepro publicy listed? | Yes, NanoRepro is a public company listed on ETR. |
| What is the stock symbol of NanoRepro? | NanoRepro trades under NN6 ticker. |
| When did NanoRepro go public? | NanoRepro went public in 2008. |
| Who are competitors of NanoRepro? | Similar companies to NanoRepro include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of NanoRepro? | NanoRepro's current market cap is $19.0M |
| What is the current revenue growth of NanoRepro? | NanoRepro revenue growth between 2023 and 2024 was -92%. |
| Is NanoRepro profitable? | Yes, NanoRepro is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
